{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:11:55Z","timestamp":1777936315240,"version":"3.51.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"41","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.vaccine.2009.07.027","type":"journal-article","created":{"date-parts":[[2009,7,31]],"date-time":"2009-07-31T12:48:26Z","timestamp":1249044506000},"page":"5612-5619","source":"Crossref","is-referenced-by-count":68,"title":["Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine"],"prefix":"10.1016","volume":"27","author":[{"given":"Ali","family":"Rowhani-Rahbar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constance","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James P.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances B.","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janine T.","family":"Bryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen E.","family":"Hawes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noel S.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura A.","family":"Koutsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"31","key":"10.1016\/j.vaccine.2009.07.027_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/oxfordjournals.jncimonographs.a003479","article-title":"Chapter 1: human papillomavirus and cervical cancer\u2014burden and assessment of causality","author":"Bosch","year":"2003","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"1","key":"10.1016\/j.vaccine.2009.07.027_bib2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2009.07.027_bib3","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.vaccine.2006.06.014","article-title":"Chapter 13: current findings from prophylactic HPV vaccine trials","volume":"24","author":"Koutsky","year":"2006","journal-title":"Vaccine"},{"issue":"50","key":"10.1016\/j.vaccine.2009.07.027_bib4","doi-asserted-by":"crossref","first-page":"8352","DOI":"10.1016\/j.vaccine.2007.09.027","article-title":"HPV vaccine efficacy in preventing persistent cervical HPV infection: a systematic review and meta-analysis","volume":"25","author":"La Torre","year":"2007","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2009.07.027_bib5","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1503\/cmaj.070948","article-title":"Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials","volume":"177","author":"Rambout","year":"2007","journal-title":"CMAJ"},{"issue":"21","key":"10.1016\/j.vaccine.2009.07.027_bib6","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa020586","article-title":"A controlled trial of a human papillomavirus type 16 vaccine","volume":"347","author":"Koutsky","year":"2002","journal-title":"N Engl J Med"},{"issue":"9447","key":"10.1016\/j.vaccine.2009.07.027_bib7","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2009.07.027_bib8","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet Oncol"},{"issue":"9518","key":"10.1016\/j.vaccine.2009.07.027_bib9","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2009.07.027_bib10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.AOG.0000192397.41191.fb","article-title":"Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial","volume":"107","author":"Mao","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"11","key":"10.1016\/j.vaccine.2009.07.027_bib11","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","article-title":"High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up","volume":"95","author":"Villa","year":"2006","journal-title":"Br J Cancer"},{"issue":"19","key":"10.1016\/j.vaccine.2009.07.027_bib12","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2009.07.027_bib13","doi-asserted-by":"crossref","unstructured":"The FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369(9576):1861\u20138.","DOI":"10.1016\/S0140-6736(07)60852-6"},{"issue":"19","key":"10.1016\/j.vaccine.2009.07.027_bib14","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"issue":"9580","key":"10.1016\/j.vaccine.2009.07.027_bib15","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2009.07.027_bib16","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/ijc.23260","article-title":"Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women","volume":"122","author":"Perez","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2009.07.027_bib17","series-title":"American association for cancer research annual meeting","article-title":"Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16\/18 L1 VLP AS04 candidate vaccine","author":"Gall","year":"2007"},{"key":"10.1016\/j.vaccine.2009.07.027_bib18","unstructured":"Food and Drug Administration. Available at http:\/\/www.fda.gov\/bbs\/topics\/NEWS\/2006\/NEW01385.html."},{"issue":"32","key":"10.1016\/j.vaccine.2009.07.027_bib19","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1016\/j.vaccine.2008.05.038","article-title":"Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy","volume":"26","author":"Kim","year":"2008","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2009.07.027_bib20","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/jnci\/djh104","article-title":"Projected clinical benefits and cost-effectiveness of a human papillomavirus 16\/18 vaccine","volume":"96","author":"Goldie","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.vaccine.2009.07.027_bib21","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/ijc.11334","article-title":"A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16\/18 vaccine","volume":"106","author":"Goldie","year":"2003","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.vaccine.2009.07.027_bib22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0168-1702(02)00199-5","article-title":"Health economics and cervical cancer prevention: a global perspective","volume":"89","author":"Goldie","year":"2002","journal-title":"Virus Res"},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2009.07.027_bib23","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.vaccine.2006.05.116","article-title":"Chapter 21: modelling the impact of HPV vaccines on cervical cancer and screening programmes","volume":"24","author":"Garnett","year":"2006","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2009.07.027_bib24","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/sj.bjc.6604462","article-title":"Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India","volume":"99","author":"Diaz","year":"2008","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.vaccine.2009.07.027_bib25","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1371\/journal.pmed.0030138","article-title":"Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses","volume":"3","author":"Barnabas","year":"2006","journal-title":"PLoS Med"},{"issue":"6","key":"10.1016\/j.vaccine.2009.07.027_bib26","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.290.6.781","article-title":"Potential health and economic impact of adding a human papillomavirus vaccine to screening programs","volume":"290","author":"Kulasingam","year":"2003","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.vaccine.2009.07.027_bib27","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3201\/eid0901.020168","article-title":"Cost-effectiveness of a potential vaccine for human papillomavirus","volume":"9","author":"Sanders","year":"2003","journal-title":"Emerg Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2009.07.027_bib28","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.3201\/eid1011.040222","article-title":"Evaluating human papillomavirus vaccination programs","volume":"10","author":"Taira","year":"2004","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2009.07.027_bib29","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3201\/eid1301.060438","article-title":"Model for assessing human papillomavirus vaccination strategies","volume":"13","author":"Elbasha","year":"2007","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2009.07.027_bib30","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1503\/cmaj.061709","article-title":"Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection","volume":"177","author":"Brisson","year":"2007","journal-title":"CMAJ"},{"issue":"29","key":"10.1016\/j.vaccine.2009.07.027_bib31","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1016\/j.vaccine.2007.04.086","article-title":"The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada","volume":"25","author":"Brisson","year":"2007","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2009.07.027_bib32","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/aje\/kwk059","article-title":"Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty","volume":"165","author":"Van de Velde","year":"2007","journal-title":"Am J Epidemiol"},{"issue":"10","key":"10.1016\/j.vaccine.2009.07.027_bib33","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/01.olq.0000179892.78342.79","article-title":"Human papillomavirus vaccines: what does the future hold for preventing cervical cancer in resource-poor settings through immunization programs?","volume":"32","author":"Jacob","year":"2005","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2009.07.027_bib34","unstructured":"People Search. Available at: http:\/\/www.peoplesearch.com\/."},{"key":"10.1016\/j.vaccine.2009.07.027_bib35","unstructured":"Accurint. Available at: http:\/\/www.accurint.com\/."},{"issue":"16","key":"10.1016\/j.vaccine.2009.07.027_bib36","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1001\/jama.287.16.2114","article-title":"The 2001 Bethesda system: terminology for reporting results of cervical cytology","volume":"287","author":"Solomon","year":"2002","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.vaccine.2009.07.027_bib37","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of human papillomavirus 16\/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial","volume":"298","author":"Hildesheim","year":"2007","journal-title":"JAMA"},{"issue":"27\/28","key":"10.1016\/j.vaccine.2009.07.027_bib38","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1016\/j.vaccine.2006.04.068","article-title":"Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16 and 18","volume":"24","author":"Villa","year":"2006","journal-title":"Vaccine"},{"issue":"21","key":"10.1016\/j.vaccine.2009.07.027_bib39","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1016\/j.vaccine.2007.02.069","article-title":"Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine","volume":"25","author":"Fraser","year":"2007","journal-title":"Vaccine"},{"issue":"26","key":"10.1016\/j.vaccine.2009.07.027_bib40","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1016\/j.vaccine.2007.03.049","article-title":"Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6\/11\/16\/18 L1 virus-like particle (VLP) vaccine","volume":"25","author":"Olsson","year":"2007","journal-title":"Vaccine"},{"issue":"14","key":"10.1016\/j.vaccine.2009.07.027_bib41","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/sim.1394","article-title":"On the analysis of viral load endpoints in HIV vaccine trials","volume":"22","author":"Hudgens","year":"2003","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.vaccine.2009.07.027_bib42","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.bjc.6600688","article-title":"Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis","volume":"88","author":"Clifford","year":"2003","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.vaccine.2009.07.027_bib43","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1258\/095646206778145550","article-title":"Enrolment of 22.000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing","volume":"17","author":"Lehtinen","year":"2006","journal-title":"Int J STD AIDS"},{"issue":"4","key":"10.1016\/j.vaccine.2009.07.027_bib44","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1258\/095646206776253453","article-title":"Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy","volume":"17","author":"Lehtinen","year":"2006","journal-title":"Int J STD AIDS"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X0901038X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X0901038X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T16:22:52Z","timestamp":1558455772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X0901038X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":44,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S0264410X0901038X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2009.07.027","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}